FDA Grants Priority Review to Merck ’s New Drug Application for Vericiguat
KENILWORTH, N.J.--(BUSINESS WIRE) July 16, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Drugs & Pharmacology | Food and Drug Administration (FDA) | Grants | Merck | New Drug Applications | USA Health